Mostrar el registro sencillo del ítem

dc.contributor.authorSoriano, Vicente (1)
dc.contributor.authorBarreiro, Pablo
dc.contributor.authorCachay, Edward R.
dc.contributor.authorKottilil, Shyamasundaran
dc.contributor.authorFernandez-Montero, José V.
dc.contributor.authorMendoza, Carmen de
dc.date2020-10
dc.date.accessioned2021-03-23T15:00:15Z
dc.date.available2021-03-23T15:00:15Z
dc.identifier.issn2049-937X
dc.identifier.urihttps://reunir.unir.net/handle/123456789/11112
dc.description.abstractDespite the availability of both effective preventive vaccines and oral antivirals, over 250 million people are chronically infected with the hepatitis B virus (HBV). Globally, chronic hepatitis B is the leading cause of hepatocellular carcinoma, which represents the third cause of cancer mortality, accounting for nearly 1 million annual deaths. Current oral nucleos(t)ide therapy with tenofovir or entecavir suppresses serum HBV-DNA in most treated patients, but rarely is accompanied by HBsAg loss. Thus, treatment has to be given lifelong to prevent viral rebound. A broad spectrum of antivirals that block the HBV life cycle at different steps are in clinical development, including entry inhibitors, cccDNA disrupters/silencers, translation inhibitors, capsid assembly modulators, polymerase inhibitors and secretion inhibitors. Some of them exhibit higher potency than current oral nucleos(t)ides. Drugs in more advanced stages of clinical development are bulevirtide, JNJ-6379, ABI-H0731, ARO-HBV and REP-2139. To date, only treatment with ARO-HBV and with REP-2139 have resulted in HBsAg loss in a significant proportion of patients. Combination therapies using distinct antivirals and/or immune modulators are expected to maximize treatment benefits. The current goal is to achieve a 'functional cure', with sustained serum HBsAg after drug discontinuation. Ultimately, the goal of HBV therapy will be virus eradication, an achievement that would require the elimination of the cccDNA reservoir within infected hepatocytes.es_ES
dc.language.isoenges_ES
dc.publisherTherapeutic Advances in Infectious Diseasees_ES
dc.relation.ispartofseries;vol. 7
dc.relation.urihttps://journals.sagepub.com/doi/10.1177/2049936120965027es_ES
dc.rightsopenAccesses_ES
dc.subjectantiviral therapyes_ES
dc.subjectbulevirtidees_ES
dc.subjectcccDNAes_ES
dc.subjectchronic hepatitis Bes_ES
dc.subjectcombination therapyes_ES
dc.subjectgene editinges_ES
dc.subjecthepatitis deltaes_ES
dc.subjectresistancees_ES
dc.subjectEmerginges_ES
dc.subjectScopuses_ES
dc.titleAdvances in hepatitis B therapeuticses_ES
dc.typereviewes_ES
reunir.tag~ARIes_ES
dc.identifier.doihttp://doi.org/10.1177/2049936120965027


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem